关注肿瘤本身还是超越肿瘤——预测胰腺癌预后的定量影像生物标志物系统综述与Meta分析
该系统综述与Meta分析纳入43项研究,评估CT和MRI定量影像生物标志物对胰腺癌预后的预测价值,重点关注肿瘤固有特征之外的身体成分参数。较大肿瘤尺寸、较低骨骼肌放射密度、较低骨骼肌指数、存在肌少性肥胖、较低腰大肌指数、较高内脏与皮下脂肪面积比及较低内脏脂肪指数与更差总生存期显著相关。作者认为诊断时的身体成分影像生物标志物可能对预测患者预后有重要作用,但需进一步前瞻性多中心大样本研究验证并转化为临床实践。
要点
- 较低骨骼肌指数和较低腰大肌指数与更差总生存期相关,HR分别为1.65(95%CI 1.39-1.96)和2.20(95%CI 1.74-2.78)。
- 较低骨骼肌指数患者无复发生存期更差,HR为1.78(95%CI 1.46-2.18)。
- 较大肿瘤尺寸、较低骨骼肌放射密度、存在肌少性肥胖、较高内脏与皮下脂肪面积比及较低内脏脂肪指数均与更差总生存期显著相关。
核心结论
- 诊断胰腺癌时提示身体成分的影像生物标志物可能对预测患者预后有重要作用,需进一步前瞻性多中心大样本研究验证并转化为临床实践。
研究设计与样本
- 系统综述与Meta分析,检索PubMed、EMBASE和Cochrane Library数据库2014年1月至2024年8月发表的关于CT或MRI定量影像生物标志物预测胰腺癌预后的文章,纳入43项研究,采用纽卡斯尔-渥太华量表评估纳入研究质量,使用随机效应模型计算合并风险比(HR)和95%置信区间(CI),评估总生存期(OS)和无复发生存期(RFS)等生存结局。
诊断标准与关键数值
- 较大肿瘤尺寸、较低骨骼肌放射密度、较低骨骼肌指数(SMI)、存在肌少性肥胖、较低腰大肌指数(PMI)、较高内脏与皮下脂肪面积比及较低内脏脂肪指数与显著更差的总生存期(OS)相关。
- 较低SMI的合并HR为1.65(95%CI 1.39-1.96),较低PMI的合并HR为2.20(95%CI 1.74-2.78)。
- 较低SMI患者无复发生存期(RFS)更差,HR为1.78(95%CI 1.46-2.18)。
- 亚组分析发现研究来源地区和干预类型可能是SMI预测OS异质性的潜在因素。
局限性
- 需要进一步开展前瞻性多中心大样本研究进行验证并转化为临床实践。
- 亚组分析发现研究来源地区和干预类型可能是SMI预测OS异质性的潜在因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To evaluate the prognostic value of quantitative imaging biomarkers derived from computed tomography (CT) and magnetic resonance imaging (MRI) for pancreatic cancer (PC), with a particular focus on body composition parameters beyond the traditional intrinsic features of the tumor.
METHODS: PubMed, EMBASE, and Cochrane Library databases were searched for articles on quantitative imaging biomarkers obtained from CT or MRI in predicting PC prognosis published between January 2014 and August 2024. The Newcastle-Ottawa scale was used to assess the quality of the included studies. Survival outcomes, such as overall survival (OS) and recurrence-free survival (RFS), were evaluated. The pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using a random-effects model. In case of high heterogeneity, subgroup analyses and sensitivity analyses were performed to identify potential sources of heterogeneity among the studies.
RESULTS: We performed a meta-analysis of ten imaging biomarkers investigated in 43 included studies. Larger tumor size, lower skeletal muscle radiodensity, lower skeletal muscle index (SMI), presence of sarcopenic obesity, lower psoas muscle index (PMI), higher visceral to subcutaneous adipose tissue area ratio, and lower visceral adipose tissue index were associated with significantly worse OS. In particular, lower SMI and lower PMI had relatively high HRs (1.65 for SMI, 95% CI 1.39-1.96, and 2.20 for PMI, 95% CI 1.74-2.78). Patients with lower SMI exhibited poorer RFS (HR 1.78, 95% CI 1.46-2.18). Subgroup analyses identified the origin region of the study and intervention type as potential factors of heterogeneity for SMI in predicting OS.
CONCLUSIONS: Imaging biomarkers indicating body composition at PC diagnosis may play an important role in predicting patient prognosis. Further prospective multi-center studies with large sample sizes are needed for validation and translation into clinical practice.
引用
- Wang Z, Zhu L, Wang Y, et al. Looking at or beyond the tumor - a systematic review and meta-analysis of quantitative imaging biomarkers predicting pancreatic cancer prognosis. Abdom Radiol (NY). 2025. PMID: 40195140. doi:10.1007/s00261-025-04919-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。